AVALGLUCOSIDASE ALFA (Nexviadyme®)

Clinical Indication

Pompe disease

Comments

In line with NICE TA821. This product should be used by specialist centres only. At the time of classification LLR is not a site of a specialist centre

Date of classification

October 2022

Do not prescribe

Drugs not recommended for use in LLR because of lack of evidence of clinical effectiveness, cost prioritization or concerns over safety